Semaglutide May Lower Fracture Risk

People with type 2 diabetes already face a higher risk of broken bones. So when researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, might actually lower that risk, it caught attention fast.

The findings come from a team at Stanford University Medical Center. Dr. Sun H. Kim led the work, along with former endocrinology fellow Dr. Jairo Noreña. They presented their results at ENDO 2026, the Endocrine Society’s annual meeting in Chicago this June.

Here’s what they did. The researchers pulled data from a massive electronic health record database called Atropos Health Eos. It covers more than 161 million patients nationwide. From that pool, they identified nearly 60,000 adults with type 2 diabetes.

Some patients took semaglutide. Others took dulaglutide, a different GLP-1 receptor agonist. Some took oral weight loss medications instead, either phentermine and topiramate or bupropion and naltrexone. The team tracked everyone for an average of more than three and a half years.

The numbers told an interesting story. Patients on semaglutide had 794 fractures during the study. The comparison group had 1,045. That works out to roughly a 15 percent lower fracture risk with semaglutide.

What makes this notable is the weight loss angle. Semaglutide also led to greater weight loss than the other treatments. In a more tightly matched analysis of over 4,000 patient pairs, semaglutide users saw a bigger drop in BMI. They also kept more of that weight off after a year.

This matters because rapid weight loss has long been linked to bone loss. Doctors have worried that GLP-1 drugs might speed up that process. The concern centers on lean muscle loss, which reduces the mechanical stress that helps keep bones strong. Less stress can mean weaker bones over time.

There’s another layer to this. People with type 2 diabetes already carry an extra fracture risk. Hypoglycemia can cause falls. Chronic inflammation and high blood sugar can weaken bone quality, too, sometimes in ways a standard bone scan won’t catch.

So finding that semaglutide might protect against fractures was a surprise. It runs counter to what many specialists expected going in. Dr. Kim noted that the results seem to separate weight loss from bone loss, at least in this case. She suggested semaglutide could have some kind of protective effect on bone that scientists don’t fully understand yet.

It helps to remember what semaglutide actually is. It belongs to a class of drugs called GLP-1 receptor agonists. The brand name is Ozempic for type 2 diabetes, and Wegovy for chronic weight management in adults with obesity. Both require a prescription. Both come with known side effects, mostly involving digestion.

Bone health hasn’t typically been part of that conversation. That could start to change as more data rolls in.

There’s an important caveat here, though. This was a retrospective study. Researchers looked back at existing records instead of running a controlled trial. The results haven’t gone through peer review yet, since they came from a conference presentation rather than a published paper. The authors themselves say prospective studies are still needed before anyone draws firm conclusions.

Still, this adds a useful data point. It matters most for patients and doctors managing type 2 diabetes, especially those already worried about bone fragility. It doesn’t change current prescribing guidelines. But it does suggest the relationship between weight loss drugs and bone health is more complicated than people once assumed.